Jonathan Wong
The Latest
-
Tightening Grip on Labor Market: U.S. Job Growth Slows, Unemployment Dips to 3.6%
In the latest employment report by the Labor Department, U.S. nonfarm payrolls rose by 209,000 in June, marking a significant slowdown from May's revised figure of 306,000. While the job growth rate fell short of the predicted 225,000 by Reuters' economists, the unemployment rate shrank to 3.6% from 3.7% in the previous month. 
In the latest employment report by the Labor Department, U.S. nonfarm payrolls rose by 209,000 in June, marking a significant slowdown from May's revised figure of 306,000. While the job growth rate fell short of the predicted 225,000 by Reuters' economists, the unemployment rate shrank to 3.6% from 3.7% in the previous month. -
Global Gold Rush: World Central Banks Continue to Stockpile, Gold Prices Set for a Potential Rise
The World Gold Council (WGC) has released new data indicating a continuation of gold acquisitions by central banks worldwide, with Turkey being the notable exception due to its extensive sell-off. The data shows that in May, eight central banks increased their gold reserves with a net purchase of 50 tons. However, Turkey's decision to sell another 63 tons of gold in May led to a net decrease of 27 tons in the global gold holdings of central banks. 
The World Gold Council (WGC) has released new data indicating a continuation of gold acquisitions by central banks worldwide, with Turkey being the notable exception due to its extensive sell-off. The data shows that in May, eight central banks increased their gold reserves with a net purchase of 50 tons. However, Turkey's decision to sell another 63 tons of gold in May led to a net decrease of 27 tons in the global gold holdings of central banks. -
A New Hope for Alzheimer's Treatment: FDA Approves Leqembi, Paving the Way for Insurance Coverage
The U.S. Food and Drug Administration (FDA) granted approval for Leqembi, an Alzheimer's disease drug developed by Japanese pharmaceutical company Eizai and Massachusetts-based Biogen on Thursday, July 6. 
The U.S. Food and Drug Administration (FDA) granted approval for Leqembi, an Alzheimer's disease drug developed by Japanese pharmaceutical company Eizai and Massachusetts-based Biogen on Thursday, July 6. -
Riding the AI Wave: Silicon Valley Seizes the Lifeline Amid Market Slump
Last year, as the Federal Reserve began an aggressive cycle of rate hikes, Silicon Valley responded by initiating significant layoffs and reducing project numbers in order to cut costs. This turmoil saw the NASDAQ Composite Index plummet by around 30% and the U.S. primary market, dominated for years by tech start-ups, came to a standstill. This led many to believe that the U.S. tech sector might be facing a crisis similar to the 2000 internet bubble, and that a long-term slump might be inevitable. 
Last year, as the Federal Reserve began an aggressive cycle of rate hikes, Silicon Valley responded by initiating significant layoffs and reducing project numbers in order to cut costs. This turmoil saw the NASDAQ Composite Index plummet by around 30% and the U.S. primary market, dominated for years by tech start-ups, came to a standstill. This led many to believe that the U.S. tech sector might be facing a crisis similar to the 2000 internet bubble, and that a long-term slump might be inevitable. -
U.S. Aims to Restrict Chinese Companies From Using 'American Cloud', Experts Call it Extreme Suppression
According to a report by the Wall Street Journal on July 4, the Biden administration is preparing to restrict Chinese companies from using U.S. cloud computing services. 
According to a report by the Wall Street Journal on July 4, the Biden administration is preparing to restrict Chinese companies from using U.S. cloud computing services. -
Federal Reserve Research Predicts: Rate Cuts Might Not Surface Until 2026
Recent documents from the Federal Reserve suggest that interest rate cuts might be delayed until 2026. 
Recent documents from the Federal Reserve suggest that interest rate cuts might be delayed until 2026. -
U.S. Dollar Bulls Retreat as Federal Reserve's Interest Rate Hike Cycle Nears an End: Hedge Funds Unwind Bets
Hedge funds are swiftly unwinding their bullish bets on the U.S. dollar, as the Federal Reserve may soon end its current interest rate hike cycle. 
Hedge funds are swiftly unwinding their bullish bets on the U.S. dollar, as the Federal Reserve may soon end its current interest rate hike cycle. -
Virgin Galactic Marks First Commercial Space Flight, Yet Shares Take a Nosedive
Nearly two decades since its inception, the aviation company Virgin Galactic has reached a milestone with the launch of its long-awaited first commercial space flight. 
Nearly two decades since its inception, the aviation company Virgin Galactic has reached a milestone with the launch of its long-awaited first commercial space flight. -
Sweet No More? Sugar-Free Beverages Face Potential Carcinogen Concerns
Recent research suggests that acesulfame, a sweetener widely used in low-sugar and sugar-free food and drinks, could be a potential carcinogen, a development that could send ripples through the food industry. 
Recent research suggests that acesulfame, a sweetener widely used in low-sugar and sugar-free food and drinks, could be a potential carcinogen, a development that could send ripples through the food industry. -
Biden Takes on Sleep Apnea with CPAP Machine, Visible Facial Marks Evident
According to a report by Bloomberg, White House officials announced on the 28th that President Biden has recently started using a Continuous Positive Airway Pressure (CPAP) machine to treat his long-standing condition, sleep apnea. 
According to a report by Bloomberg, White House officials announced on the 28th that President Biden has recently started using a Continuous Positive Airway Pressure (CPAP) machine to treat his long-standing condition, sleep apnea.
